Staphylococcus aureus Vaccine Polypeptide Combinations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines for Staphylococcus aureus lack effectiveness in protecting against multiple pathologies and do not elicit sufficient opsonic responses, particularly for hematic spread and pneumonia, highlighting the need for improved antigens that can provide broad-spectrum protection.
Innovation Solution
Identification and combination of specific S. aureus polypeptides, such as clfA, clfB, esxA, esxB, Hla, isdA, isdB, isdC, sasD, sdrC, sdrD, spa, and sdrE2, which can be used alone or with saccharides to create immunogenic compositions that induce a robust immune response, including opsonic activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If a single antigen vaccine (e.g., V710 based on IsdB) is used, then the vaccine can be simple to manufacture and administer, but it fails to provide protection against multiple S. aureus pathologies and does not elicit sufficient opsonic responses
Solution Approach 1:
The patent combines multiple S. aureus antigens (including IsdB, clfA, clfB, eap, ebpS, efb, emp, esaC, FnBA, FnBB, Hla, hlgB, hlgC, isdA, isdC, isdG, isdH, isdI, lukD, lukE, lukF, lukS, nuc, sasA, sasB, sasC, sasD, sasF, sdrC, sdrD, spa, and sdrE2) into a single vaccine composition. This merging of multiple antigens allows the vaccine to target various S. aureus pathologies simultaneously while maintaining a manageable formulation that can be manufactured and administered as a single product.
Solution Approach 2:
The patent creates a multi-functional vaccine composition that addresses multiple S. aureus infections (hematic spread, pneumonia, skin infections, and other pathologies) through a single vaccine formulation. The combination of diverse antigens enables the vaccine to elicit broad immune responses including opsonic activity, neutralizing antibodies, and cell-mediated immunity, making it universally effective against various disease manifestations.
2Device complexity
If polysaccharide-based vaccines (e.g., StaphV AXTM) are used, then the vaccine formulation is simple, but the vaccine fails to reduce infections compared to placebo
Solution Approach 1:
The patent employs a composite vaccine formulation that integrates multiple protein antigens with varying immunogenic properties. This composite approach combines antigens that elicit different types of immune responses (humoral, cellular, opsonic), creating a synergistic effect that significantly improves reliability and effectiveness compared to simple polysaccharide formulations alone.
3Ease of operation
If vaccines target specific S. aureus virulence factors, then the vaccine can be designed with clear mechanism of action, but the vaccine may be ineffective against other S. aureus diseases due to differential expression of virulence factors
Solution Approach 1:
The patent segments the S. aureus virulence profile into multiple discrete antigen targets, each associated with specific disease manifestations. By dividing the protective antigens into distinct components (clfA for clumping factor, eap for extracellular adhesin, Hla for hemolysin, etc.), the vaccine design achieves clarity in mechanism of action for each antigen while the combination provides broad coverage across different diseases.
Data Source
AI summary
An effective Staphylococcus aureus vaccine may require several antigenic components, and so various combinations of S. aureus antigens are identified for use in immunisation. These polypeptides may optionally be used in combination with S. aureus saccharides.